Class: Antituberculosis agent
- Powder for injection 1 g (as sulfate)/vial
Interferes with protein synthesis.
The T max is 1 to 2 h following IM administration.
Approximately 52% of capreomycin is excreted unchanged in the urine within 12 h.
Indications and Usage
Treatment of tuberculosis concomitantly with other antituberculous agents.
Dosage and AdministrationAdults
IV/IM 1 g/day (max, 20 mg/kg/day) for 60 to 120 days, followed by 1 g IV or IM 2 or 3 times weekly.
- Reconstitute following manufacturer's instructions.
- Inspect reconstituted solution visually before administration. Do not administer if solution is cloudy, discolored, or contains particulate matter. Reconstituted solution may acquire a pale straw color and darken with time, but this is not associated with loss of potency.
- For IM administration, give reconstituted capreomycin by deep IM injection into large muscle mass.
- For IV infusion, dilute reconstituted capreomycin in 100 mL of sodium chloride 0.9% injection and infuse prescribed dose over 60 min.
- Do not add other medications to IV container.
Store powder for injection at controlled room temperature (59° to 86°F). Reconstituted solution may be stored for up to 24 h in refrigerator (36° to 46°F).
Drug InteractionsAminoglycosides (eg, streptomycin)
May increase the risk of respiratory paralysis and renal function impairment.Nondepolarizing neuromuscular blocking agents (eg, tubocurarine)
Neuromuscular blockade may be enhanced.
Laboratory Test Interactions
None well documented.
Ototoxicity; hearing loss.
Leukocytosis; leukopenia; eosinophilia; thrombocytopenia.
Decreased bromosulfophthalein excretion; abnormal liver function tests.
Hypersensitivity (including febrile reactions, urticaria, maculopapular rash); pain; induration and excessive bleeding at injection site; sterile abscesses.
MonitorIM injection sites
Assess IM injection sites for pain, bleeding, induration, or evidence of abscess formation. Inform health care provider if noted and significant.Mycobacterial studies/Susceptibility tests
Assess mycobacterial studies and susceptibility tests before and periodically throughout therapy to detect possible resistance.
Safety and efficacy not established.
Dosage reduction is necessary.
Special Risk Patients
Use with great caution in patients with preexisting renal insufficiency or auditory impairment.
May occur during therapy.
Renal injury with tubular necrosis, elevation of BUN or serum creatinine, and abnormal urinary sediment may occur.
May occur; perform audiometric measurements and assess vestibular function prior to therapy and at regular intervals during treatment.
- Advise patient that medication will be prepared and administered by a health care provider in a health care setting.
- Review dosing schedule and prescribed length of therapy with patient. Emphasize to patient that treatment will be lengthy.
- Instruct patient to report the following symptoms to health care provider: ringing in the ears, vertigo (feeling of whirling motion), dizziness, hearing loss, itching, rash, pain, lumps, bleeding at injection site.
Copyright © 2009 Wolters Kluwer Health.